Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.20 Consensus Target Price from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $29.20.

Several equities research analysts recently issued reports on the company. Stifel Nicolaus cut Kura Oncology from a "buy" rating to a "hold" rating and cut their price target for the company from $26.00 to $19.00 in a research note on Monday. JMP Securities restated a "market outperform" rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research report on Monday, September 9th. StockNews.com lowered shares of Kura Oncology from a "hold" rating to a "sell" rating in a report on Thursday, August 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th.

Kura Oncology Stock Up 0.3 %

Kura Oncology stock traded up $0.06 during mid-day trading on Wednesday, reaching $18.27. The company's stock had a trading volume of 409,481 shares, compared to its average volume of 909,013. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology has a 12 month low of $7.41 and a 12 month high of $24.17. The business's 50 day simple moving average is $19.56 and its 200 day simple moving average is $20.25. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -8.42 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.04. During the same period last year, the firm earned ($0.53) earnings per share. Kura Oncology's revenue for the quarter was up .0% compared to the same quarter last year. As a group, research analysts anticipate that Kura Oncology will post -2.45 earnings per share for the current year.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in KURA. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the 1st quarter valued at $110,000. Quarry LP acquired a new position in shares of Kura Oncology during the second quarter worth $196,000. Saxon Interests Inc. bought a new position in Kura Oncology during the 1st quarter worth $201,000. Entropy Technologies LP acquired a new position in Kura Oncology during the 1st quarter worth about $218,000. Finally, HighVista Strategies LLC bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $345,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.